Minireview: The effects of spcies ortholog and SNP variation on receptors for free fatty acids

Molecular Endocrinology

Volumn 27, Issue 8, 2013, Pages 1177-1187

  Hudson, Brian D ^a   Murdoch, Hannah ^a   Milligan, Graeme ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 40; CELL SURFACE RECEPTOR; FATTY ACID; FFAR1 PROTEIN, HUMAN; FFAR3 PROTEIN, HUMAN; G PROTEIN COUPLED RECEPTOR 43, HUMAN; G-PROTEIN COUPLED RECEPTOR 43, HUMAN; LIGAND;

HUMAN; LIGAND BINDING; NONHUMAN; ORTHOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SPECIES; SPECIES DIFFERENCE; AMINO ACID SEQUENCE; ANIMAL; BIOSYNTHESIS; GENETICS; METABOLISM; MOLECULAR GENETICS; MOUSE; SEQUENCE ALIGNMENT;

AMINO ACID SEQUENCE; ANIMALS; FATTY ACIDS, NONESTERIFIED; HUMANS; LIGANDS; MICE; MOLECULAR SEQUENCE DATA; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CELL SURFACE; RECEPTORS, G-PROTEIN-COUPLED; SEQUENCE ALIGNMENT;

EID: 84880787550     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2013-1085     Document Type: Review

References (73)

1. Blad CC, Tang C, Offermanns S. G protein-coupled receptors for energy metabolites as new therapeutic targets. Nat Rev Drug Discov. 2012;11:603-619.
2. Smith, NJ. Low affinity GPCRs for metabolic intermediates: challenges for pharmacologists. Front Endocrinol (Lausanne) 2012;3:1.
3. Ryan KK, Seeley RJ. Food as a hormone. Science. 2013;339:918-919.
4. Stoddart LA, Smith NJ, Milligan G. International Union of Pharmacology. LXXI. Free fatty acid receptors FFA1, -2, and -3: pharmacology and pathophysiological functions. Pharmacol Rev. 2008; 60:405-417.
5. Brown AJ, Goldsworthy SM, Barnes AA, et al. The orphan G protein- coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem. 2003; 278:11312-11319.
6. Schmidt J, Smith NJ, Christiansen E, et al. Selective orthosteric free fatty acid receptor 2 (FFA2) agonists: identification of the structural and chemical requirements for selective activation of FFA2 versus FFA3. J Biol Chem. 2011;286:10628-10640.
7. Wolever TM, Josse RG, Leiter LA, Chiasson JL. Time of day and glucose tolerance status affect serum short-chain fatty acid concentrations in humans. Metabolism. 1997;46:805-811.
8. Cummings JH, Pomare EW, Branch WJ, Naylor CP, Macfarlane GT. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut. 1987;28:1221-1227.
9. Fredriksson R, Lagerström MC, Lundin LG, Schiöth HB. The Gprotein- coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol. 2003;63:1256-1272.
10. Sum CS, Tikhonova IG, Neumann S, et al. Identification of residues important for agonist recognition and activation in GPR40. J Biol Chem. 2007;282:29248-29255.
11. Stoddart LA, Smith NJ, Jenkins L, Brown AJ, Milligan G. Conserved polar residues in transmembrane domains V, VI, and VII of free fatty acid receptor 2 and free fatty acid receptor 3 are required for the binding and function of short chain fatty acids. J Biol Chem. 2008;283:32913-32924.
12. Watson SJ, Brown AJ, Holliday ND. Differential signaling by splice variants of the human free fatty acid receptor GPR120. Mol Pharmacol. 2012;81:631-642.
13. Shimpukade B, Hudson BD, Hovgaard CK, Milligan G, Ulven T. Discovery of a potent and selective GPR120 agonist. J Med Chem. 2012;55:4511-4515.
14. Itoh Y, Kawamata Y, Harada M, et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature. 2003;422:173-176.
15. Edfalk S, Steneberg P, Edlund H. Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes. 2008;57:2280-2287.
16. Hirasawa A, Tsumaya K, Awaji T, et al. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med. 2005;11:90-94.
17. Oh DY, Talukdar S, Bae EJ, et al. GPR120 is an ω-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell. 2010;142:687-698.
18. Taneera J, Lang S, Sharma A, et al. A systems genetics approach identifies genes and pathways for type 2 diabetes in human islets. Cell Metab. 2011;16:122-134.
19. Kebede M, Alquier T, Latour MG, Semache M, Tremblay C, Poitout V. The fatty acid receptor GPR40 plays a role in insulin secretion in vivo after high-fat feeding. Diabetes. 2008;57:2432-2437.
20. Maslowski KM, Vieira AT, Ng A, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature. 2009;461:1282-1286.
21. Bellahcene M, O'Dowd JF, Wargent ET, et al. Male mice that lack the G-protein-coupled receptor GPR41 have low energy expenditure and increased body fat content. Br J Nutr. 2012;31:1-10.
22. Ichimura A, Hirasawa A, Poulain-Godefroy O, et al. Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human. Nature. 2012;483:350-354.
23. Milligan G, Stoddart LA, Smith NJ. Agonism and allosterism: the pharmacology of the free fatty acid receptors FFA2 and FFA3. Br J Pharmacol. 2009;158:146-153.
24. Hudson BD, Smith NJ, Milligan G. Experimental challenges to targeting poorly characterized GPCRs: uncovering the therapeutic potential for free fatty acid receptors. Adv Pharmacol. 2011;62: 175-218.
25. Briscoe CP, Peat AJ, McKeown SC, et al. Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. Br J Pharmacol. 2006;148:619-628.
26. Christiansen E, Urban C, Merten N, et al. Discovery of potent and selective agonists for the free fatty acid receptor 1 [FFA(1)/GPR40], a potential target for the treatment of type II diabetes. J Med Chem. 2008;51:7061-7064.
27. Hudson BD, Due-Hansen ME, Christiansen E, et al. Defining the molecular basis for the first potent and selective orthosteric agonists of the FFA2 free fatty acid receptor. J Biol Chem. 2013;288:17296-17312
28. Hudson BD, Tikhonova IG, Pandey SK, Ulven T, Milligan G. Extracellular ionic locks determine variation in constitutive activity and ligand potency between species orthologs of the free fatty acid receptors FFA2 and FFA3. J Biol Chem. 2012;287:41195-41209.
29. Hudson BD, Christiansen E, Tikhonova IG, et al. Chemically engineering ligand selectivity at the free fatty acid receptor 2 based on pharmacological variation between species orthologs. FASEB J. 2012;26:4951-4965.
30. Bergman EN. Energy contributions of volatile fatty acids from the gastrointestinal tract in various species. Physiol Rev. 1990;70:567-590.
31. Strasser A, Wittmann HJ, Buschauer A Schneider EH, Seifert R. Species-dependent activities of G-protein-coupled receptor ligands: lessons from histamine receptor orthologs. Trends Pharmacol Sci. 2013;34:13-32.
32. Milligan G. Orthologue selectivity and ligand bias: translating the pharmacology of GPR35. Trends Pharmacol Sci. 2011;32:317-325.
33. Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev. 2009;41: 89-295.
34. Insel PA, Tang CM, Hahntow I, Michel MC. Impact of GPCRs in clinical medicine: monogenic diseases, genetic variants and drug targets. Biochim Biophys Acta. 2007;1768:994-1005.
35. Xiong Y, Swaminath G, Cao Q, et al. Activation of FFA1 mediates GLP-1 secretion in mice. Evidence for allosterism at FFA1. Mol Cell Endocrinol. 2013;369:119-129.
36. Luo J, Swaminath G, Brown SP, et al. A Potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents. PLoS One. 2012;7:e46300.
37. Burant CF, Viswanathan P, Marcinak J, et al. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2012;379: 1403-1411.
38. Kaku K, Araki T, Yoshinaka R. Randomized, double-blind, doseranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes. Diabetes Care. 2013;36:245-250.
39. 1000 Genomes Project Consortium, Abecasis GR, Altshuler D, et al. A map of human genome variation from population-scale sequencing. Nature. 2010;467:1061-1073.
40. Ogawa T, Hirose H, Miyashita K, Saito I, Saruta T. GPR40 gene Arg211His polymorphism may contribute to the variation of insulin secretory capacity in Japanese men. Metabolism. 2005;54:296-299.
41. Hamid YH, Vissing H, Holst B, et al. Studies of relationships between variation of the human G protein-coupled receptor 40 Gene and type 2 diabetes and insulin release. Diabet Med. 2005;22:74-80.
42. Smith NJ, Stoddart LA, Devine NM, Jenkins L, Milligan G. The action and mode of binding of thiazolidinedione ligands at free fatty acid receptor 1. J Biol Chem. 2009;284:17527-17539.
43. Vettor R, Granzotto M, De Stefani D, et al. Loss-of-function mutation of the GPR40 gene associates with abnormal stimulated insulin secretion by acting on intracellular calcium mobilization. J Clin Endocrinol Metab. 2008;93:3541-3550.
44. Kalis M, Levéen P, Lyssenko V, Almgren P, Groop L, Cilio CM. Variants in the FFAR1 gene are associated with beta cell function. PLoS One. 2007;2:e1090.
45. Lin DC, Zhang J, Zhuang R, et al. AMG837: a novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents. PLoS One. 2011;6:e27270.
46. Christiansen E, Due-Hansen ME, Urban C, et al. Free fatty acid receptor 1 (FFA1/GPR40) agonists: mesylpropoxy appendage lowers lipophilicity and improves ADME properties. J Med Chem. 2012;55:6624-6628.
47. Christiansen E, Due-Hansen ME, Urban C, et al. Discovery of a potent and selective free fatty acid receptor 1 agonist with low lipophilicity and high oral bioavailability. J Med Chem. 2013;56: 982-992.
48. Tan CP, Feng Y, Zhou YP, et al. Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice. Diabetes. 2008. 2008;57:2211-2219.
49. Negoro N, Sasaki S, Mikami S, et al. Discovery of TAK-875: a potent, selective, and orally bioavailable GPR40 agonist. ACS Med Chem Lett. 2010;1:290-294.
50. Humphries PS, Benbow JW, Bonin PD, et al. Synthesis and SAR of 1,2,3,4-tetrahydroisoquinolin-1-ones as novel G-protein-coupled receptor 40 (GPR40) antagonists. Bioorg Med Chem Lett. 2009; 19:2400-2403.
51. Christiansen E, Urban C, Grundmann M, et al. Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties. J Med Chem. 2011;54:6691-6703.
52. Yashiro H, Tsujihata Y, Takeuchi K, Hazama M, Johnson PR, Rorsman P. The effects of TAK-875, a selective G protein-coupled receptor 40/free fatty acid 1 agonist, on insulin and glucagon secretion in isolated rat and human islets. J Pharmacol Exp Ther. 2011; 340:483-489.
53. Steneberg P, Rubins N, Bartoov-Shifman R, Walker MD, Edlund H. The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. Cell Metab. 2005;1:245-258.
54. Latour MG, Alquier T, Oseid E, et al. GPR40 is necessary but not sufficient for fatty acid stimulation of insulin secretion in vivo. Diabetes. 2007;56:1087-1094.
55. Lan H, Hoos LM, Liu L, et al. Lack of FFAR1/GPR40 does not protect mice from high-fat diet-induced metabolic disease. Diabetes. 2008;57:2999-3006.
56. Ma J, Novack A, Nashashibi I, et al. Aryl GPR120 receptor agonists and uses thereof. International patent application, WO 2010/ 048207. April 29, 2010.
57. Le Poul E, Loison C, Struyf S, et al. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem. 2003;278:25481-25489.
58. Sina C, Gavrilova O, Förster M, et al. G protein-coupled receptor 43 is essential for neutrophil recruitment during intestinal inflammation. J Immunol. 2009;183:7514-7522.
59. Hong YH, Nishimura Y, Hishikawa D, et al. Acetate and propionate short chain fatty acids stimulate adipogenesis via GPCR43. Endocrinology. 2005;146:5092-5099.
60. Ge H, Li X, Weiszmann J, et al. Activation of G protein-coupled receptor 43 in adipocytes leads to inhibition of lipolysis and suppression of plasma free fatty acids. Endocrinology. 2008;149: 4519-4526.
61. Tolhurst G, Heffron H, Lam YS, et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes. 2012;61:364-371.
62. Kebede MA, Alquier T, Latour MG, Poitout V. Lipid receptors and islet function: therapeutic implications? Diabetes Obes Metab 2009;11(suppl 4):10-20.
63. Bjursell M, Admyre T, Göransson M, et al. 2011 Improved glucose control and reduced body fat mass in free fatty acid receptor 2-deficient mice fed a high-fat diet. Am J Physiol Endocrinol Metab. 300:E211-E220.
64. Kimura I, Inoue D, Maeda T, et al. Short-chain fatty acids and ketones directly regulate sympathetic nervous system via G proteincoupled receptor 41 (GPR41). Proc Natl Acad Sci USA. 2011;108: 8030-8035.
65. Xiong Y, Miyamoto N, Shibata K, et al. Short-chain fatty acids stimulate leptin production in adipocytes through the G proteincoupled receptor GPR41. Proc Natl Acad Sci USA. 2004;101: 1045-1050.
66. Zaibi MS, Stocker CJ, O'Dowd J, et al. Roles of GPR41 and GPR43 in leptin secretory responses of murine adipocytes to short chain fatty acids. FEBS Lett. 2010;584:2381-2386.
67. Leonard JN, Chu ZL, Bruce MA, Boatman PD. GPR41 and modulators thereof for the treatment of insulin-related disorders. PCT Int Appl. 2006;WO2006052566.
68. Sawzdargo M, George SR, Nguyen T, Xu S, Kolakowski LF, O'Dowd BF. A cluster of four novel human G protein-coupled receptor genes occurring in close proximity to CD22 gene on chromosome 19q13.1. Biochem Biophys Res Commun. 1997;239:543-547.
69. Liaw CW, Connolly DT. Sequence polymorphisms provide a common consensus sequence for GPR41 and GPR42. DNA Cell Biol. 2009;28:550-560.
70. Moore K, Zhang Q, Murgolo N, Hosted T, Duffy R. Cloning, expression, and pharmacological characterization of the GPR120 free fatty acid receptor from cynomolgus monkey: comparison with human GPR120 splice variants. Comp Biochem Physiol B Biochem Mol Biol. 2009;154:419-426.
71. Galindo MM, Voigt N, Stein J, et al. G protein-coupled receptors in human fat taste perception. Chem Senses. 2012;37:123-139.
72. Arkawa K, Nishimura T, Sugimoto Y, Takahashi H. Novel isoindolin- 1-one derivative. International patent application,WO2010/ 104195. September 16, 2010.
73. Hashimoto N, Sasaki Y, Nakama C, Ishikawa M. Novel phenylisoxayol- 3-ol derative. US patent application, US 2010/0130559. May 27, 2010.